Register

Basket Updated

0

Items added

View Featured Offers >>
1% for the planet logo

Resources results for "PD 1"

  • Products (280)
  • Resources (1509)

Resources

The regions recognized by our PD-1 and PD-L1 antibodies are as follows:

PD-1 (EH33) Mouse mAb (IHC-Specific) #43248 binds the extracellular domain.
PD-1 (D7D5W) XP® Rabbit mAb (Mouse Specific) #84651 binds the intracellular domain.
PD-1 (D4W2J) XP® Rabbit mAb #86163 binds the intracellular domain.
PD-L1 (E1L3N®) XP® Rabbit mAb #13684 binds the intracellular domain.
PD-L1 (Extracellular Domain Specific) (E1J2J) Rabbit mAb #15165 binds the extracellular domain.
PD-L1 (405.9A11) Mouse mAb #29122 binds the intracellular domain.
PD-L1 (D4H1Z) Rabbit mAb #60475 binds the extracellular domain.
PD-L1 (D5V3B) Rabbit mAb (Mouse Specific; IHC Specific) #64988 binds the intracellular domain.
PD-L1 (Extracellular Domain Specific) (D8T4X) Rabbit mAb #86744 binds the extracellular domain.

PD-L1

PD-L1/PD1 immune checkpoint helps tumor cells evade detection by the immune system. Highly specific and sensitive PD-L1 antibody now available from CST.

Cell Signaling Technology, Inc. Announces PD-L1 Antibody, Important to Cancer Immunotherapy Research

Cell Signaling Technology, Inc. (CST) of Danvers, MA, announced today that it has introduced a highly specific PD-L1 rabbit monoclonal antibody (mAb).

Resources

Unfortunately, our PD-1 or PD-L1 antibodies have not been tested in neutralization assays. Therefore, we cannot guarantee their performance.


 

Resources

We currently offer three products targeting PD-L2:

Our PD-L2 (D7U8C) XP® Rabbit mAb #82723 recognizes endogenous levels of total human PD-L2 protein and was produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Arg168 of human PD-L2 protein. This antibody works well in western blots and IHC when probing human samples. #82723 is not cross-reactive with mouse PD-L2.

We also offer PD-L2 (D7U8C™) XP® Rabbit mAb (BSA and Azide Free) #99337, which is the same clone and product as #82723, but supplied in a BSA and azide free format.

Our PD-L2 (D6L5A) Rabbit mAb #49189 recognizes endogenous levels of total mouse PD-L2 protein and was produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala85 of mouse PD-L2 protein. This antibody works well by IHC when probing mouse samples. However, it is not sensitive enough to detect mouse PD-L2 by western blot at endogenous levels.

We also o…

More Than a Phenotype: a Guide to Assessing Tumor-infiltrating Immune Cell Types and Functions

We created a set of guides from the perspective of observing immune cells in intact tumor tissue. Given the technical constraints of multiplex IHC, we aimed to provide the minimum set of most well-established markers enabling identification of each cell type.

Parkinson’s Disease Resource Center

Pivotal Cancer Immunology Targets

CST offers a growing portfolio of products for the study of immune checkpoint targets in cancer, including several receptor-ligand pairs.

SignalStar™ Spatial Profiling

SignalStar™ Spatial Profiling is a revolutionary new tool for spatial biology research with fully customizable and highly-validated antibody IHC panels.

Cell Signaling Technology and The Michael J. Fox Foundation Partner to Develop High-Quality Antibody Tools for Parkinson's Disease Research

CST and The Michael J. Fox Foundation (MJFF) announce a partnership to develop high-quality monoclonal antibodies against promising Parkinson’s disease (PD) targets.

Immuno-Oncology: Can T Cells Be Re-trained to Attack Cancer?

Harnessing the power of the immune system's T cells to attack and treat cancer is a promising research area that may lead to highly effective therapies.

Immunotherapy: Empowering Nature’s Anti-Tumor Artillery - Part I

Why not take advantage of our own immune system and the best of its weaponry, the T-cells, to fight cancer? This is the basis of immunotherapy.

Characterizing the Autophagic-Lysosomal Pathway in Parkinson’s Disease

These antibodies to CNS markers can help study how LRRK2 mutations impact the autophagic-lysosomal pathway (ALP) and contribute to Parkinson's disease.

Immune Checkpoint Signaling in the Tumor Microenvironment

Interact with this signaling pathway showing immune checkpoint regulation in the tumor microenvironment, including targets such as PD-L1, GITR, TIM-3, CTLA-4, OX40, and more.

Multiplex IHC

Multiplex IHC - Being able to visualize multiple targets simultaneously is important in research fields like immunology & oncology. Learn more here.

Resources

Our PD-L1 (D4H1Z) Rabbit mAb #60475 is approved for western immunoblot in mouse samples. We also offer our PD-L1 (D5V3B) Rabbit mAb (Mouse Specific; IHC Specific) #64988, however this antibody should only be used for IHC and is not approved for western blotting. 

Unravelling Parkinson’s Disease: The Role of Mitophagy, Autophagy & Lysosomal Processing

PD is characterized by functional loss in dopaminergic neurons, believed to be caused by disruption of proteins involved in cell quality control pathways.

AD/PD 2023: Therapeutics, Diagnostics & Mechanisms Linked to a Classic Alzheimer’s Disease Theory

Therapeutic developments in treating Alzheimer’s, novel diagnostic tools, and new insights into neurodegeneration mechanisms were key topics at AD/PD 2023.

Adaptive Immune Response

Products and Related Resources for Adaptive Immune Response SARS-CoV-2 Research

Resources

HDLM-2 and bone marrow-derived macrophage cells are PD-L2 positive.

PC-3, Jurkat, and RAW 264.7 cells are PD-L2 negative.

The following tissues are PD-L2 positive: human colon carcinoma, mediastinal large B-cell lymphoma, human tonsil, human non-small cell lung carcinoma, paraffin-embedded 4T1 metastatic tumor in mouse lung, and mouse spleen.

Resources

The predicted molecular weight of PD-L1 is 33 kDa (based on amino acid composition). However, in most models, PD-L1 migrates at an observed molecular weight of 40-50 kDa on Tris-Glycine gels. This discrepancy between the predicted and the observed molecular weights is a result of glycosylation [see Li, C. et al. (2016) Nat. Commun. 7:12632 (PMID: 27572267; https://www.ncbi.nlm.nih.gov/pubmed/27572267)].

Resources

The predicted molecular weight of PD-L2 is 31 kDa (based on amino acid composition). However, in most models, PD-L2 migrates at an observed molecular weight of 45-60 kDa on Tris-Glycine gels. This discrepancy between the predicted and the observed molecular weights is a result of glycosylation [see Wang, H et al. (2017) Oncoimmunology 6(7), e1327494 (PMID: 28811964; https://www.ncbi.nlm.nih.gov/pubmed/28811964)].

Lieping Chen, YCC, Awarded CST Innovation & Translational Research Award for Outstanding Scientists of Chinese Heritage

Lieping Chen, Yale University Cancer Center, Awarded Cell Signaling Technology Innovation and Translational Research Award for Outstanding Scientists of Chinese Heritage

Targeting TIGIT for Immunotherapy and T Cell Exhaustion

Given the limited but remarkable success of immune checkpoint blockade, recent efforts have been focused on identifying new targets for improving immunotherapy effectiveness in the immunosuppressive tumor microenvironment. One such target is T cell immunoreceptor with Ig and ITIM domains (TIGIT).

Immunophenotyping Basics

Immunophenotyping is a technique that uses antibodies to allow the identification and quantification of particular cell types within a heterogenous population.

Immunotherapy: Empowering Nature’s Anti-tumor Artillery - Part II

Advancements in immunotherapeutics against cancer include receptor agonists, adoptive cell transfer, anti-cancer vaccines, and combination therapies.

Cancer Immunotherapy Awareness Month: Fueling the Next Scientific Breakthrough

Checkpoint inhibitors, targeted antibodies, adoptive cell therapy, and cancer vaccines are promising immunotherapies with recent therapeutic developments.

Taking Out the Mitochondria in Parkinson’s Disease

Proteomics can help elucidate mitochondrial homeostasis and dysfunction, inflammasome activation, and the role of parkin in Parkinson's disease.

B7-H3 & B7-H4

Highly specific and sensitive rabbit mAbs against B7 family targets, B7-H3 & B7-H4, are proven to outperform existing clones by WB.

Demystifying Antibody Panel Design for Multiplex IHC

How do you design a panel of antibodies and fluorophores for mIHC? Learn how to set up a protocol that avoids epitope masking by optimizing antibody order.